Pfizer Stops Torcetrapib Trials in Interest of Patient Safety
[In Dec 2006] Pfizer suspended a large, Phase 3 trial evaluating the investigational cardiovascular therapy torceptrapib/atorvastatin (T/A) due to an increased rate of mortality (death) in patients. more...

Going Off Patent
Starting in 2010, the pharmaceutical industry faces one of the biggest waves of patent expirations ever, affecting dozens of top-selling drugs. Here are are some of the drugs facing looming generic competition. more...

Big Pharma Faces Grim Prognosis
Generic competition is expected to wipe $67 billion from top companies' annual U.S. sales between 2007 and 2012 as more than three dozen drugs lose patent protection. [...] At the same time, the industry's science engine has stalled. more...

Physics-based modeling may accelerate the drug-development process.
"Through mathematical modeling of complex biological systems, you can make predictions about how to improve them in a directed, designed way," says Bruce Tidor, a computational biologist at MIT who led the study. "That's usually not what's done in medicine." more ...